Biopharma | January 11, 2026
Prokaryotics and Basilea team up to tackle deadly fungal infections
The partnership aims to develop a first-in-class broad-spectrum antifungal to combat life-threatening invasive infections
The partnership aims to develop a first-in-class broad-spectrum antifungal to combat life-threatening invasive infections
The decision follows an interim analysis conducted when roughly half of the patients had completed their Day 84 visit
NGD Infection Prevention was formed to scale the delivery of sequence-based transmission detection
LANXESS will highlight its commitment to combatting antimicrobial resistance by presenting science-based disinfection solutions
This milestone marks the first-ever NDA submission to the U.S. FDA for a drug, fully discovered and developed by an Indian pharmaceutical company
As with any medicine, the MHRA will keep the safety of gepotidacin under close review
This case report is jointly authored by US clinicians from leading hospitals, Houston Methodist Hospital, Weill Cornell Medical College and Johns Hopkins
EMBLAVEOTM is the first and only monobactam/?-lactamase inhibitor combination antibiotic therapy approved by the USFDA
MRX-5 is a novel benzoxazole antibiotic developed for the treatment of mycobacteria infections, particularly infections caused by non-tuberculous Mycobacteria
Sun Pharma has obtained rights from MSD to develop, manufacture and commercialise Tedizolid Phosphate in India
Subscribe To Our Newsletter & Stay Updated
